SCHEMBL4672127

SCHEMBL4672127

Nc1ccc(Cc2coc(C(=O)C=C(O)C(=O)O)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
CYP3A4 P08684 2/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ITGB1 P05556 4/20 0.35
ITGA5 P08648 4/20 0.35
ITGB3 P05106 3/20 0.34
ITGAV P06756 3/20 0.34
CDC25B P30305 1/20 0.33
CASP6 P55212 1/20 0.33
RCE1 Q9Y256 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
RARA P10276 1/20 0.32
RXRA P19793 1/20 0.32
MAPT P10636 2/20 0.31
RAB9A P51151 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672124 1.00 ALDH1A1 (0.39) ALDH1A1CYP3A4TSHRTDP1ITGB1
SCHEMBL4675016 0.87 IDH1 (0.38) RARARXRAPLA2G10PLA2G2ALMNA
SCHEMBL4675020 0.87 IDH1 (0.38) RARARXRAPLA2G10PLA2G2ALMNA
SCHEMBL4671127 0.86 SRD5A2 (0.41) ALDH1A1RARARXRAMAPTLMNA
SCHEMBL4673710 0.86 CTBP2 (0.35) ALDH1A1CA12CA1CA2CA9
SCHEMBL4673707 0.86 CTBP2 (0.35) ALDH1A1CA12CA1CA2CA9
SCHEMBL4671126 0.86 SRD5A2 (0.41) ALDH1A1RARARXRAMAPTLMNA
SCHEMBL4671595 0.84 KMT2A (0.50) ALDH1A1TSHRRARARXRAMAPT
SCHEMBL4671590 0.84 KMT2A (0.50) ALDH1A1TSHRRARARXRAMAPT
SCHEMBL4671722 0.83 HDAC1 (0.37) ALDH1A1CYP3A4TSHRMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885CYP3A4 4/4885TSHR 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.